Navigation Links
Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
Date:8/11/2008

Pursing International Market Opportunities for the Company's Medical

Countermeasures

ANNAPOLIS, Md., Aug. 11 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that Lord Lewis Moonie has joined the Company as a special UK government advisor.

Lord Moonie will assist PharmAthene in exploring interest and support for the Company's biodefense programs and product candidates within the UK government.

"We are honored to welcome Lord Moonie to PharmAthene in this advisory capacity and are delighted to have the opportunity to leverage his significant knowledge of the UK biodefense industry and amongst our NATO allies," stated David P. Wright, President and Chief Executive Officer of PharmAthene. "Lord Moonie's medical background and extensive experience as a Member of Parliament, as well as his oversight of the Research Establishment at Porton Down, which included recombinant vaccines for plague and anthrax, will be invaluable to us as we continue to expand awareness and the market for our biodefense countermeasures among our Allies. We view Lord Moonie's appointment as an important step in the execution of our international strategy to meet the urgent needs of nations internationally requiring medical countermeasures."

Lord Moonie retired from the UK's House of Common in 2005 after eighteen years as Member of Parliament for Kirkcaldy. During this time, Lord Moonie spent three and a half years as a junior minister in the Ministry of Defence (MOD), with responsibility for all of MOD's Science and Technology, including the Defence Diversification Agency. Prior to this he was a consultant in public health medicine in the NHS. Following his service in the MOD, Lord Moonie was chairman of a pre-legislative committee of both the House of Commons and House of Lords which scrutinized the draft Civil Contingencies Bill.

Since 2004, Lord Moonie has served as a non-executive director of AEA Technology, which provides a wide range of consultancy and advisory services, and program management to government in the fields of energy management and the environment.

Lord Moonie is a member of the Board of Trustees of the charity Skillforce, and is a consultant in a variety of fields, including energy, health services and communications. He currently sits on the European Advisory Board of Northrop Grumman and is a non-executive director of Party Gaming.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

-- SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine

-- Valortim(R) -- a fully human monoclonal antibody for the prevention and treatment of anthrax infection

-- Protexia(R) -- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

-- RypVax(TM) -- a recombinant dual antigen vaccine for plague a third generation rPA anthrax vaccine.

For more information about PharmAthene, please visit http://www.PharmAthene.com.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, unforeseen safety issues, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's public disclosure filings with the U.S. Securities and Exchange Commission (the "SEC"). Furthermore, there can be no assurance that our engagement of Lord Moonie will result in the award of any contracts with the UK government or any ministries, departments, agencies and the like thereof to PharmAthene. Copies of PharmAthene's public disclosure filings are available from its investor relations department.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biovail Concerned Shareholders Welcome Glass Lewis Evaluation
2. Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec
3. Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Boards Directors
4. RiskMetrics Group (ISS) and Glass Lewis & Co. Support Nabi Biopharmaceuticals Proposed Asset Sale
5. NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide
6. BioStorage Technologies Serves as Repository for Landmark Study of Coronary Artery Disease
7. Serving Those Who Serve Our Country: Medical Device Company Answers the Call of a U.S. Combat Hospital in Iraq
8. Group Hotel Rate Ends Friday: Reserve Now for Leadership Development Conference June 4-6
9. MedThink Hires Two Executives to Serve its Growing Pharmaceutical Client Base
10. Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University
11. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... The American Medical Informatics Association ... the National Coordinator for Health IT (ONC) outlining a measurement approach to interoperability ... available when and where it was needed. The organization of health informatics professionals ...
(Date:5/25/2016)... ... May 25, 2016 , ... Lady had been battling arthritis since the ... in her left knee. Lady’s owner Hannah sought the help of Dr Jeff Christiansen ... to repair her cruciate ligament and help with the pain of Lady’s arthritis. Dr ...
(Date:5/24/2016)...   MedyMatch Technology Ltd ., the data analytics healthcare ... support tools in the emergency room, announced today that it ... Technology Industries (IATI) BioMed Conference. The Conference ... National Life Sciences and Technology Week, and is being held ... Tel Aviv, Israel . Gene Saragnese ...
(Date:5/23/2016)... ... ... blood donations in South Texas and across the nation is growing. , But according to ... are on the decline. In fact, donations across the country are at their lowest point ... the last four years alone. , There is no substitute for blood. , “We want ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
Breaking Biology News(10 mins):